GUSTO study researchers said maternal lifestyle, fetal genetic, and fetal epigenetic factors affect birth weight and early childhood adiposity.
The company, still collecting utility data, anticipates that this more complex analysis will lead to better personalization of health and wellness strategies for its clients.
The collaborators plan to collect samples that will allow them insight into participants' microbiomes in order to understand disease mechanisms over time.
By studying variants in PCSK9, researchers reported the therapies targeting the gene would have some of the same effects as statins.
The company plans to recruit one million patients from Mexico over three years and then expand to Columbia, Argentina, and Brazil.
The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.
The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.
The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
Researchers uncovered 60 genomic loci associated with birth weight and found that those regions are also linked to risk for type 2 diabetes and other diseases.
Researchers saw both short- and long-term changes in metabolite profiles in blood plasma from individuals who'd undergone Roux-en-Y gastric bypass surgery.
The core technology uses proximity-ligated amplification and the firm will build it into tests for type I diabetes as well as highly multiplexed assays.
A genome-wide association and fine-mapping study of Samoans led to a missense mutation in the CREBRF gene that seems to correspond with increased fat storage.
The company plans to launch the 12-protein panel as a CLIA test for longitudinal monitoring of cardiovascular disease, kidney disease, and diabetes.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.
In the study, the partners will perform exome sequencing and whole-genome array genotyping on more than 9,000 individuals with diabetes or with diabetic relatives.
The portal offers access to genotype, phenotype, and clinical data related to type 2 diabetes as well as computational tools for querying the information.
The addition of certain kinds of information could help clinical labs determine whether variants of uncertain significance are pathogenic or benign.
Researchers diagnosed almost 70 percent of the neurometabolic cases they tackled, using exome sequence data for dozens of affected children and their families.
The funding will support development of tests that detect cell-free DNA methylation patterns indicative of disease in specific tissues of the body.
CeMeT, short for Center for Metagenomics, was founded in 2014 as a spinout from genetic diagnostics firm CeGaT in Tübingen.
A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.
A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.